DGX vs MTD
Quest Diagnostics and Mettler Toledo, both Healthcare
Mettler Toledo is the larger company at $23B against $22B. On trailing earnings DGX is the cheaper of the two at a P/E of 24.5 against 34.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year DGX returned +28% against +20% for MTD. The RyuScore puts MTD ahead, 74 against 63 out of 100.
| Figure | DGX | MTD |
|---|---|---|
| Last close | $231 | $1551 |
| Market cap | $22B | $23B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 24.5 | 34.9 |
| 1-year return | +28% | +20% |
| 5-year return | +65% | -0.3% |
| RyuScoresector-relative, 1–10 | 63/100 | 74/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Quest Diagnostics
Revenue of $3.0B in Q2 2026, net income $320M. Its largest reported line is Diagnostic Information Services Business, 98% of the disclosed total.
Mettler Toledo
Revenue of $1.0B in Q2 2026, net income $233M. Its largest reported line is Us Operations Segment Member, 34% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.